Syndax Pharmaceuticals Inc (NASDAQ: SNDX) kicked off on Monday, up 4.01% from the previous trading day, before settling in for the closing price of $9.98. Over the past 52 weeks, SNDX has traded in a range of $8.58-$22.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -15.16% over the past five years. While this was happening, its average annual earnings per share was recorded -0.02%. With a float of $82.48 million, this company’s outstanding shares have now reached $86.05 million.
Let’s look at the performance matrix of the company that is accounted for 270 employees. In terms of profitability, gross margin is -3.44%, operating margin of -786.59%, and the pretax margin is -757.52%.
Syndax Pharmaceuticals Inc (SNDX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Syndax Pharmaceuticals Inc is 4.15%, while institutional ownership is 116.09%. The most recent insider transaction that took place on Jul 16 ’25, was worth 12,033. In this transaction Chief Financial Officer of this company sold 1,296 shares at a rate of $9.29, taking the stock ownership to the 92,450 shares. Before that another transaction happened on Jul 16 ’25, when Company’s Chief Executive Officer sold 7,534 for $9.29, making the entire transaction worth $69,953. This insider now owns 298,661 shares in total.
Syndax Pharmaceuticals Inc (SNDX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.02% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 28.41% during the next five years compared to -15.16% drop over the previous five years of trading.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Trading Performance Indicators
Take a look at Syndax Pharmaceuticals Inc’s (SNDX) current performance indicators. Last quarter, stock had a quick ratio of 5.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 20.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.87, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -2.57 in one year’s time.
Technical Analysis of Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) saw its 5-day average volume 2.47 million, a positive change from its year-to-date volume of 2.15 million. As of the previous 9 days, the stock’s Stochastic %D was 51.23%.
During the past 100 days, Syndax Pharmaceuticals Inc’s (SNDX) raw stochastic average was set at 31.52%, which indicates a significant decrease from 78.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.59 in the past 14 days, which was lower than the 0.72 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.92, while its 200-day Moving Average is $13.33.
